These days, one doesn’t experience the news on these platforms before seeing the memes and reactions—the reaction and the ...

The 2026 trading year has kicked into gear, and while some stocks are already pushing higher into the green, others are ...

Humanoid robots are a dead end; the real breakthrough is a self-improving SuperNet that manufactures itself — and everything ...

Insilico now has a pipeline of more than 40 AI-developed drugs it is developing for conditions such as cancer, bowel and kidney disease.

Cosmologists are increasingly entertaining a radical possibility: that the cosmos might fold back on itself so that, on the ...

Introduction Application of artificial intelligence (AI) tools in the healthcare setting gains importance especially in the domain of disease diagnosis. Numerous studies have tried to explore AI in ...

In December 2025, J.P. Morgan upgraded Recursion Pharmaceuticals after REC-4881 showed rapid, durable polyp burden reductions and a favorable safety profile in familial adenomatous polyposis patients, ...

Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

NuScale stock is up about 37% in the brand-new year, helped by the Trump administration's recent award of $2.7 billion to ...

Blockchain security firm CertiK has recently released pivotal updates that shed light on regulatory shifts and technical ...